Abcellera Biologics Inc
- Bolsa
- EE. UU.
- País / Región
- USA
- Fecha de salida a bolsa
- 11 de diciembre de 2020
- Empleados
- 562
- Sitio web
- www.abcellera.com
Rango de valoración compuesto · conservador $3.8–$4.3 / razonable $5.8–$7.8 / optimista $9.7–$11. A $6.47, Dentro del rango de valor intrínseco razonable.
Al publicar $6.47 (18 de julio de 2026)
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Historia
PróximamenteEsta sección se está completando; vuelve pronto.
Posición en el sector
PróximamenteEsta sección se está completando; vuelve pronto.
Aún no hay análisis sobre este valor en tu idioma.
